Vendor Intelligence Report: Bulk Peptide Wholesale

Published 3 Jul 2026. 24-page investigative report on who is behind Bulk Peptide Wholesale: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Bulk Peptide Wholesale’s public lab signal is unusually strong for a young storefront, but it is not uniform. Across 20 Finnrick lab tests, the record is 19 pass / 1 fail — an overall pass rate of 95%. The buying read is product-specific: GHK-Cu and Retatrutide are the clearest strengths, while CJC-1295 grades weakly despite passing samples and Ipamorelin is the only product in the current BPW set with a Finnrick failure. The report also shows ratings compress under stricter methodology, making lot-level verification more important than a simple pass count.

Beyond the numbers, BPW looks less like an independently established company and more like a wholesale-facing storefront inside the Bulk Peptide Supply structure. Site terms, domain-registration signals, BBB/contact records, and court materials point back to that brand family and its identified principal; the public site relaunch did not add a manufacturer, importer of record, authorized-channel directory, or vial-authentication system.

The investigation also surfaces two buyer-recourse issues that matter on a wholesale order. BPW’s visible payment model still centers on Zelle, Venmo, and Cash App-style rails with a 10-unit minimum, limiting chargeback leverage. Its named COA lab, MDx BioAnalytical Laboratory, continued to display expired/pending ISO/IEC-17025 accreditation language after the March 2026 audit, so post-March COAs should be treated as weaker evidence unless matched to the vial and independently confirmed.

A documented copycat/brand-confusion dispute adds another verification layer: Justia and another docket source carry conflicting status signals, while PACER confirmation was not available in this run. The scoped X/web promotion scan was comparatively cleaner, finding no obvious BPW referral-code ecosystem, though private social channels were not swept.

Inside the full report:

  • Per-product pass/fail interpretation and methodology-divergence charts for all 8 tested peptides
  • Corporate-control map tying BPW site terms, domain records, BBB/contact trail, and litigation materials to Bulk Peptide Supply
  • COA traceability analysis of MDx accreditation status and vial-to-batch verification gaps
  • Payment-rail and wholesale-recourse assessment for the 10-unit MOQ model
  • Federal trademark docket comparison showing the unresolved copycat-litigation status conflict
  • Scoped X/web affiliate and coupon-network sweep with coverage caveats

Risk assessment

  • COA reliability / lab-accreditation risk — high: BPW relies on MDx COAs while MDx states ISO/IEC-17025 certificate expired/pending after March 2026; post-March COAs lack active accreditation backing.
  • Product-specific testing-methodology risk — medium: BPW overall is 20 tests (19 pass / 1 fail), but CJC-1295 is 37.66%, BPC-157 58.22%, and Ipamorelin has 2 pass / 1 fail; stronger signals are GHK-Cu and Retatrutide.
  • Copycat / brand-confusion verification risk — medium: BPS litigation against O2 Media and overlapping BPW/BPS branding show brand-confusion risk; no public authorized-channel or anti-counterfeit list was found.
  • Irreversible-payment / wholesale recourse risk — medium: BPW maintains a 10-unit MOQ and Zelle/Venmo/Cash App-style payments, limiting chargeback leverage for high-dollar wholesale orders.